Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer

Olivier HUMBERT, Jean-Marc Riedinger, Jean-Marc Vrigneaud, Salim Kanoun, Inna Digay-Cochet, alina Berriolo-Riedinger, Michel Toubeau, Edouard Depardon, maud Lasserre, simon Tisserand, Pierre Fumoleau, François Brunotte and Alexandre Cochet
Journal of Nuclear Medicine April 2016, jnumed.116.172759; DOI: https://doi.org/10.2967/jnumed.116.172759
Olivier HUMBERT
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marc Riedinger
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marc Vrigneaud
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salim Kanoun
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inna Digay-Cochet
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
alina Berriolo-Riedinger
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Toubeau
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edouard Depardon
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
maud Lasserre
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
simon Tisserand
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Fumoleau
1 CENTRE GEORGES-FRANCOIS LECLERC, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Brunotte
2 LE2I UMR 6306, CNRS, Arts et Métiers, Univ. Bourgogne Franche-Comté, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Cochet
3 Centre Georges-Francois Leclerc, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Previous studies have suggested that early changes in blood flow (BF) in response to neoadjuvant chemotherapy and evaluated with 15O-water are a surrogate biomarker of outcome in women with breast cancer. This study investigates, in the triple-negative breast cancer (TNBC) subtype, the prognostic relevance of tumor BF changes in response to chemotherapy, assessed using a short dynamic 18F-FDG PET acquisition. Methods: Forty-six consecutive women with TNBC and an indication for neoadjuvant chemotherapy were prospectively included. Women benefited from a baseline 18F-FDG PET exam with a 2-min chest-centered dynamic acquisition, started at the time of 18F-FDG injection. Breast tumor perfusion was calculated from this short dynamic image using a first-pass model. This dynamic PET acquisition was repeated after the first cycle of chemotherapy to measure early changes in tumor BF (ΔBF). Delayed static PET acquisitions were also performed (90 min after 18F-FDG injection) to measure changes in tumor glucose metabolism (ΔSUVmax). The association between tumor BF, clinico-pathological characteristics and patients’ overall survival (OS) was evaluated. Results: Median baseline tumor BF was 21 ml/min/100g [range, 6-46 ml/min/100g] and did not significantly differ according to tumor size, SBR grade or Ki-67 expression. Median tumor ∆BF was -30% with highly scattered values [range, -93%;+118%]. A weak correlation was observed between ΔBF and ∆SUVmax (r=+0.40, P = 0.01). The median follow-up was 30 months (range, 6-73 months). Eight women developed recurrent disease, seven of whom died. Low overall survival was associated with menopausal history (P = 0.03), persistent or increased tumor vascularization on the interim PET (ΔBF cut-off = -30%; P = 0.03), non-breast-conserving surgery (P = 0.04) and the absence of a pathological complete response (pCR) (P = 0.01). ΔBF and pCR provided incremental prognostic stratification: 3-years OS was 100% in pCR-women; 87% in no-pCR women but achieving an early tumor BF response; and only 48% in no-pCR/no-BF response women (ΔBF cut-off=-30%, p<0.001). Conclusion: This study suggests the clinical usefulness of an early “user- and patient-friendly” 2-min dynamic acquisition to monitor breast tumor blood flow changes to neoadjuvant chemotherapy using 18F-FDG PET/CT. Monitoring tumor perfusion and angiogenesis response to treatment seems to be a promising target for PET tracers.

  • Breast
  • Oncology: Breast
  • PET
  • PET
  • blood flow
  • breast cancer
  • perfusion
  • triple-negative
  • Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Next
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer
Olivier HUMBERT, Jean-Marc Riedinger, Jean-Marc Vrigneaud, Salim Kanoun, Inna Digay-Cochet, alina Berriolo-Riedinger, Michel Toubeau, Edouard Depardon, maud Lasserre, simon Tisserand, Pierre Fumoleau, François Brunotte, Alexandre Cochet
Journal of Nuclear Medicine Apr 2016, jnumed.116.172759; DOI: 10.2967/jnumed.116.172759

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-FDG PET derived tumor blood flow changes after one cycle of neoadjuvant chemotherapy predicts outcome in triple-negative breast cancer
Olivier HUMBERT, Jean-Marc Riedinger, Jean-Marc Vrigneaud, Salim Kanoun, Inna Digay-Cochet, alina Berriolo-Riedinger, Michel Toubeau, Edouard Depardon, maud Lasserre, simon Tisserand, Pierre Fumoleau, François Brunotte, Alexandre Cochet
Journal of Nuclear Medicine Apr 2016, jnumed.116.172759; DOI: 10.2967/jnumed.116.172759
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • Getting the Most out of 18F-FDG PET Scans: The Predictive Value of 18F-FDG PET–Derived Blood Flow Estimates for Breast Cancer
  • PubMed
  • Google Scholar

Cited By...

  • Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response
  • 2-18F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion
  • Getting the Most out of 18F-FDG PET Scans: The Predictive Value of 18F-FDG PET-Derived Blood Flow Estimates for Breast Cancer
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • 18F-Fluorodihydroxyphenylalanine PET/CT at the Forefront for Initial and/or Pre-surgical Evaluation of Small Intestine Neuroendocrine Tumors
  • First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic
  • Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma – the HEPAR Primary study
Show more Clinical Investigations (Human)

Clinical (Oncology: Breast)

  • Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study
Show more Clinical (Oncology: Breast)

Similar Articles

Keywords

  • Breast
  • Oncology: Breast
  • PET
  • Blood flow
  • breast cancer
  • perfusion
  • triple-negative
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire